Institute for Leadership & Management in Health
The Institute of Leadership and Management in Health (ILMH) challenges the boundaries of uncertainty and value in healthcare. ILMH links a variety of intellectual, human and technical assets to create Value in healthcare. We invest our intellectual capital in the development of innovative financial and econometric models entirely based on outcome data to support policy decisions.
Cost of illness studies
Cost-of-illness studies measure the economic burden of a disease or diseases and estimate the maximum amount that could potentially be saved or gained if a disease were to be eradicated.
Bayesian cost effectiveness analysis
Bayesian statistical methods represent a valuable set of analytical tools that can make a powerful contribution to the decision-analytic approach to cost effectiveness analysis.
Budget impact analysis
The purpose of a budget impact analysis is to estimate the financial consequences of adoption and diffusion of a new health care intervention within a specific health care setting or system context given inevitable resource constraints.
Real Option valuation
Real options valuation applies derivative valuation techniques to capital budgeting decisions. A real option itself, is the right — but not the obligation to make an investment
R&D parametric cost analysis
The application of parametric cost analysis to pharmaceutical development can help reduce the uncertainty and the degree of approximation of the cost estimates.
Professor Giampiero Favato
- E-mail: G.Favato@kingston.ac.uk
Leader of global teams dedicated to innovation and change in pharmaceuticals, Giampiero holds an MBA from the University of Chicago and a research doctorate from Brunel University.
Francesco is presently Professor for Health Economics and Political Economics at University of Rome "Tor Vergata” (both at the Faculty of Economics and Science). He is also Professor for Health Economics at University of Rome "La Sapienza”, Faculty of Statistics.
His main contributions have dealt with Health Technology Assessment (HTA) and pharmaco-economics, welfare policies, health system analysis, and pharmaceutical economics.
Francesco was the chair of the Scientific Committee of the European Conference on Health Economics (ECHE). He is author of numerous publications, national and international, of Health Economics, HTA and Pharmaceutical Economics.
Prof. Massimo Pinzani
Dr Lior Jassur
Lior heads up a major bank’s credit research department. His previous experience includes investing, trading and analysing high yield bonds, leveraged loans and distressed investments at a range of financial institutions in the City of London over a period of more than 20 years. Lior earned a B.Sc. (Hons) in Economics and Business Finance from Brunel University, an MBA (prize winner) and a DBA from Henley Management College / Brunel University. His doctoral thesis: “An empirical study of asset value and volatility in structural credit models” won an EDAMBA prize in 2008. In addition to the thesis, Lior published several academic papers on credit risk quantification.
Dr Alessandro Capone
After completing his studies in medicine in Italy, in 1988 Alessandro started his professional cooperation with pharmaceutical industry, leading to the position of head of health economics & market access. Alessandro has held an internal position in consulting agencies as partner, supporting public healthcare bodies and life science industry in pricing and reimbursement procedures for new drugs and devices, economic evaluations as well as health technology assessments. Currently, he is a cofounder of a consulting agency which harmonizes different intellectual, human and technical assets to create value in healthcare.
- G Favato, G Baio, A Capone, A Marcellusi, S Costa, G Garganese, M Picardo, M Drummond, B Jonsson, G Scambia, P Zweifel, F S Mennini (2012) Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases. The BEST Study. Medical Care 50: 12. 1076-1085
- G Baio, A Capone, A Marcellusi, F S Mennini, G Favato (2012) Economic Burden of Human Papillomavirus-Related Diseases in Italy PLoS ONE 7: 11. e49699
- E Tragni, A Filippi, M Casula, G Favato, O Brignoli, C Cricelli, A Poli, AL for the CHECK group Catapano (2012) Risk factors distribution and cardiovascular disease prevalence in the Italian population: the CHECK study Open Journal of Epidemiology, doi: 10.4236/ojepi.2012
- F S Mennini, G Baio, G Montagano, G Cauzillo, G Locuratolo, G Becce, L Gitto, A Marcellusi, P Zweifel, A Capone, G Favato (2012) Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study BMJ Open 2: e. 00736
- F S Mennini, S Costa, G Favato, S Picardo (2009) Anti-HPV vaccination: A review of recent economic data for Italy Vaccine 27: 1. 54-61
- P Russo, A Capone, V Pieri, G Favato (2009) Can savings induced by off-patent drugs balance the increase of pharmaceutical expense associated with the high ageing rate of the Italian population? Italian Journal of Public Health 6: 3
- G Favato. High Incidence of Smoking Habit in Psoriatic Patients. The American Journal of Medicine 2008; Vol. 121, Issue 4, Page e17.
- G Favato, P Mariani, C F Print, A Capone, M Pelagatti, V Pieri, A Marcobelli, E Tragni, M G Trotta, A Zucchi, A L Catapano (2008) Effect of age and sex related therapeutic needs on general practices' prescribing costs. The ASSET (Age/Sex Standardised Estimates of Treatment) research model. Pharmacoeconomics - Italian Research Articles. 10: 2. 89-98
- G Favato, et al. (2007), ASSET (Age/Sex Standardised Estimates of Treatment): A Research Model to Improve the Governance of Prescribing Funds in Italy. PLoS ONE 2007; 2(7): e592.
- G Favato, A L Catapano (2007) Editorial: Old people and drug prescription in Italy. Results of The ASSET study. G. GERONTOL 55: 191-192